Purdue Pharma L.P. v. Accord Healthcare, Inc.
Case Number:
23-1953
Court:
Nature of Suit:
835 Patent - (ANDA) (Fed. Qst.)
Companies
Sectors & Industries:
-
January 02, 2025
'Crush-Resistant' OxyContin Patents Fail At Fed. Circ.
In one of its last major moves in 2024, the Federal Circuit decided to reject an appeal from the bankrupt maker of OxyContin, which is trying to use patent laws to block the release of a competing "crush-resistant" generic painkiller.
-
October 07, 2024
Fed. Circ. Questions If Safer OxyContin Profits Came From IP
An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other companies had ample opportunity to reach a solution and failed to do so.
-
September 12, 2023
Indian Co. Urges Fed. Circ. To Back Obviousness Of Oxy IP
Accord Healthcare Inc. has urged the Federal Circuit to uphold its win in a dispute in which bankrupt Purdue Pharma LP lost its legal effort to use patent laws to block the Indian drugmaker from launching a generic version of OxyContin.